BNP in hormone-guided treatment of heart failure

Trends in Endocrinology and Metabolism

Volumn 13, Issue 4, 2002, Pages 151-155

  Richards, A Mark ^a   Lainchbury, John G ^a   Nicholls, M Gary ^a   Troughton, Richard W ^a   Yandle, Timothy G ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; FELODIPINE; ISOSORBIDE MONONITRATE; SPIRONOLACTONE; BIOLOGICAL MARKER;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG MONITORING; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; DIGOXIN; DIURETICS; DOUBLE-BLIND METHOD; DRUG MONITORING; HEART DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; RANDOMIZED CONTROLLED TRIALS; SPIRONOLACTONE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0036583162     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(01)00554-9     Document Type: Review

References (65)

1. Massie, B.M. and Shah, N.B. (1996) The heart failure epidemic: magnitude of the problem and potential mitigating approaches. Curr. Opin. Cardiol. 11, 221-226
2. Murray, C.J.L. and Lopez, A.D., eds (1996) The Global Burden of Disease, The Harvard School of Public Health
3. Massie, B.M. and Shah, N.B. (1997) Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am. Heart J. 133, 703-712
4. Miller, R.R. et al. (1976) Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure. Differential effects of nitroprusside, phentolamine, and nitroglycerin on cardiac function and peripheral circulation. Circ. Res. 39, 127-133
5. Cohn, J.N. and Franciosa, J.A. (1977) Drug therapy. Vasodilator therapy of cardiac failure. New Engl. J. Med. 297, 27-31
6. Colucci, W.S. et al. (1980) Long-term therapy of heart failure with prazosin: a randomized double blind trial. Am. J. Cardiol. 45, 337-344
7. Packer, M. et al. (1982) Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure. New Engl. J. Med. 306, 57-62
8. Packer, M. (1983) Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. J. Am. Coll. Cardiol. 2, 841-852
9. Cohn, J.N. et al. (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. New Engl. J. Med. 314, 1547-1552
10. Packer, M. et al. (1986) Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. J. Am. Coll. Cardiol. 7, 671-680
11. Cohn, J.N. et al. (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl. J. Med. 325, 303-310
12. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl. J. Med. 316, 1429-1435
13. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl. J. Med. 325, 293-302
14. The SOLVD Investigators. (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl. J. Med. 327, 685-691
15. Bristow, M.R. et al. (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94, 2807-2816
16. Colucci, W.S. et al. (1996) Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 94, 2800-2806
17. Packer, M. et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl. J. Med. 334, 1349-1355
18. Australia/New Zealand Heart Failure Research Collaborative Group (1997) Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349, 375-380
19. CIBIS-II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13
20. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007
21. Califf, R.M. and O'Connor, C.M. (2000) β-Blocker therapy for heart failure. The evidence is in, now the work begins. JAMA 283, 1335-1337
22. Whorlow, S.L. and Krum, H. (2000) Meta-analysis of effect of β-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. Am. J. Cardiol. 86, 886-889
23. Packer, M. et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. New Engl. J. Med. 344, 1651-1658
24. Pitt, B. et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl. J. Med. 341, 709-717
25. Kiowski, W. et al. (1995) Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346, 732-736
26. Rouleau, J.L. et al. (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356, 615-620
27. Stevenson, L.W. et al. (1990) Importance of hemodynamic response to therapy in predicting survival with ejection fraction ≤20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am. J. Cardiol. 55, 1348-1354
28. Burnett, J.C. et al. (1986) Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231, 1145-1147
29. Richards, A.M. et al. (1986) Plasma α natriuretic peptide in cardiac impairment. Br. Med. J. 293, 409-412
30. Raine, A.E.G. et al. (1986) Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure, New Engl. J. Med. 315, 533-537
31. Richards, A.M. et al. (1993) Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br. Heart J. 69, 414-417
32. Davis, M. et al. (1994) Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 343, 440-444
33. Richards, A.M. et al, (1998) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97, 1921-1929
34. Richards, A.M. et al. (1999) Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 81, 114-120
35. Hunt, P.J. et al. (1995) The amino-terminal portion of pro-brain natriuretic peptide (pro-BNP) circulates in human plasma. Biochem. Biophys. Res. Commun. 214, 1175-1183
36. Hunt, P.J. et al. (1997) Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin. Endocrinol. 47, 287-296
37. Anderson, J.V. et al. (1986) The plasma atria] natriuretic peptide response to treatment of acute cardiac failure, spontaneous supraventricular tachycardia and induced re-entrant tachycardia in man. J. Hypertens. 4 (Suppl. 2) S137-S141
38. Crozier, I.G. et al. (1989) Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition. Clin. Exp. Pharmacol. Physiol. 16, 417-424
39. Webster, M.W.I. et al. (1989) Effect of reducing atrial pressure on atrial natriuretic factor and vasoactive hormones in congestive heart failure secondary to ischemic and nonischemic dilated cardiomyopathy. Am. J. Cardiol. 63, 217-221
40. Yoshimura, M. et al. (1994) Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br. Heart J. 72, 528-533
41. Murdoch, D.R. et al. (1999) Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am. Heart J. 138, 1126-1132
42. Sanderson, J.E. et al. (1995) Effect of low dose β-blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating β-blocker. Br. Heart J. 74, 502-507
43. Hara, Y. et al. (2000) Effect of β-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angioensin-converting enzyme inhibitor. Jpn. Circ. J. 64, 365-369
44. Doughty, R.N. et al. (1997) Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J. Am. Coll. Cardiol. 29, 1060-1066
45. Troughton, R.W. et al. (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126-1130
46. Cheng, V. et al. (2001) A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J. Am. Coll. Cardiol. 37, 386-391
47. Dao, Q. et al. (2001) Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J. Am. Coll. Cardiol. 37, 379-385
48. Lang, C.C. et al. (1994) Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. Am. Heart J. 127, 1635-1636
49. Fruhwald, F.M. et al. (1999) Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. Eur. Heart J. 20, 1415-1423
50. Yamamoto, K. et al. (1996) Superiority ofbrain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28, 988-994
51. Vasan, R.S. et al. (1995) Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J. Am. Coll. Cardiol. 26, 1565-1573
52. Brutsaert, D.L. et al. (1993) Diastolic failure: pathophysiology and therapeutic implications. J. Am. Coll. Cardiol. 22, 318-325
53. Swedberg, K. et al. (1999) Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. J. Card. Fail. 5, 276-282
54. Cleland, J. et al. (2001) PEP-CHF: a study of diastolic heart failure in the elderly. Data from the screening phase. Eur. J. Heart Fail. 3 (Suppl. 1) S71-S72
55. European Society of Cardiology. Working Group on Heart Failure (2001) Eur. J. Heart Fail. (2001) 3 (Suppl. 1) S1-S116
56. Nielsen, O.W. (2001) Screening by brain natriuretic peptide is cost effective to detect left ventricular systolic dysfunction in subjects at risk in general population. Eur. J. Heart Fail. 3 (Suppl. 1) S1-S2
57. Jourdain, P. et al. (2001) Evaluation ofbrain natriuretic peptide as a marker of functional status in chronic heart failure. Eur. J. Heart Fail. 3 (Suppl. 1) S1
58. Nielsen, O.W. et al. (2001) Strong prognostic value of combining N-terminal atrial natriuretic peptide and electrocardiogram to predict death in heart patients from general practice. Eur. J. Heart Fail. 3 (Suppl. 1) S5
59. Castro, A. et al. (2001) Evaluation of B-type natriuretic peptide in the diagnosis of heart failure with preserved systolic function. Eur. J. Heart Fail. 3 (Suppl. 1) S5
60. Azevedo, A. et al. (2001) Predictors of neuro-humoral response to therapeutic interventions in heart failure. Eur. J. Heart Fail. 3 (Suppl. 1) S11
61. Kuster, G.M. et al. (2001) Brain-natriuretic peptide (BNP) is a reliable marker of severity and treatment-responsiveness of congestive heart failure. Eur. J. Heart Fail. 3 (Suppl. 1) S11-S12
62. Refsgaard, J. et al. (2001) Plasma brain natriuretic peptide to predict haemodynamic changes of treatment with carvedilol in patients with congestive heart failure. Eur. J. Heart Fail. 3 (Suppl. 1) S29
63. Groenning, B.A. et al. (2001) The plasma concentration of N-terminal pro-brain natriuretic peptide is a strong marker for left ventricular volumes, myocardial mass and ejection fraction in patients with systolic heart failure. Eur. J. Heart Fail. 3 (Suppl. 1) S58-S59
64. Chen, H.H. et al. (2001) Natriuretic and renin suppressing actions of low dose subcutaneous brain natriuretic peptide administration in human heart failure. Eur. J. Heart Fail. 3 (Suppl. 1) S59
65. Colucci, W.S. et al. (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. New Engl. J. Med. 343, 246-253